SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

ST-920

PTCT·PTC THERAPEUTICS, INC.
BULLISH
Drug Impact Rating6/10
Trial phase
Filed/BLA-stage (Phase 1/2 registrational study completed)
Time to market
Potential FDA accelerated approval and commercial launch in 2027 if the BLA submission is completed in Q4 2026 and the FDA grants a standard or priority review timeline.
Why 6/10
The next hard catalyst is completion of the rolling BLA submission to the FDA, expected in Q4 2026 (by December 31, 2026). This is a near-term milestone for a BLA-stage asset that PTC just acquired for $111M, but it is a submission completion, not a regulatory decision. PTC has a diversified revenue base (Sephience, Translarna, Emflaza) so ST-920 is not a single-asset binary, capping the score at 6.
Actionable Insight BULLISH

Watch for completion of the rolling BLA submission to the FDA in Q4 2026 (by Dec 31). If submitted on time, the FDA will set a PDUFA date, likely in H2 2027, which would be the next major binary catalyst. Any delay in the BLA submission would be a negative signal. Also monitor the WORLD Symposium in February 2027 for updated clinical data.

Price Chart

Loading chart...

Executive Summary

ST-920 (isaralgagene civaparvovec) is a one-time AAV gene therapy for Fabry disease that PTC Therapeutics (PTCT) acquired from bankrupt Sangamo Therapeutics in September 2026 for $111M upfront plus up to $100M in milestones. A rolling BLA submission to the FDA for accelerated approval is expected to be completed in Q4 2026, with potential commercial launch in 2027. The Phase 1/2 STAAR study showed a positive mean annualized eGFR slope of +1.965 at 52 weeks (renal function improvement) and a favorable safety profile, and the FDA agreed this endpoint can serve as the primary basis for accelerated approval. PTC has a strong commercial infrastructure and $2.13B in cash to support a launch. The Fabry disease treatment market is approximately $2.5B and growing.

How It Works

ST-920 is a one-time gene therapy given as an intravenous infusion. It uses a harmless virus (AAV2/6) to deliver a working copy of the GLA gene into liver cells. The liver then produces the missing alpha-galactosidase A enzyme that Fabry disease patients lack, and releases it into the bloodstream. This is designed to provide a permanent or long-lasting source of the enzyme, eliminating the need for regular enzyme replacement infusions.

Trial Status

The registrational Phase 1/2 STAAR study (NCT04046224) has completed enrollment with 36 patients. Positive topline results were announced in June 2025, showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks across all 32 dosed patients. Detailed data presented in September 2025 and February 2026 showed sustained kidney function improvement and stable cardiac function. A rolling BLA submission was initiated by Sangamo in December 2025 and is expected to be completed by PTC in Q4 2026. A long-term follow-up study is ongoing.

The Two-Sided Case

▲ Bull Case5
ST-920 is a one-time gene therapy that could replace lifelong biweekly enzyme replacement infusions for Fabry disease, a clear value proposition for patients and payers.
The Phase 1/2 STAAR study showed a positive mean annualized eGFR slope of +1.965 at 52 weeks, indicating renal function improvement, and the FDA agreed this can serve as the primary basis for accelerated approval.
The therapy requires no preconditioning (no chemotherapy), simplifying administration versus some other gene therapies.
PTC has a strong commercial infrastructure from its existing rare disease products (Sephience, Translarna) and $2.13B in cash to support the launch.
Analyst consensus is bullish: 17 of 20 analysts rate Buy/Strong Buy, with a mean price target of $97.81 (51.7% upside from $64.46). Cantor Fitzgerald raised its target to $137 after the acquisition.
▼ Bear Case5
The BLA submission is based on a single-arm Phase 1/2 study (STAAR) with 32-36 patients, not a randomized controlled trial, which raises regulatory risk for full approval.
The 95% confidence interval for the eGFR slope (-0.153 to 4.083) crosses zero, meaning the result was not statistically significant at conventional levels.
Competing gene therapies from 4D Molecular Therapeutics (4D-310) and Freeline are also in development, and established ERT products (Fabrazyme, Replagal) and oral chaperone Galafold already serve the market.
PTC paid $111M upfront plus up to $100M in milestones for an asset acquired from a bankrupt company, and the $111M charge drove a GAAP EPS miss in Q3 2026.
Manufacturing and commercial-scale production of AAV gene therapies is complex and has been a bottleneck for other gene therapy launches.

Upcoming Catalysts

  • Completion of rolling BLA submission to FDA in Q4 2026 (by December 31, 2026)
  • FDA acceptance of BLA and PDUFA date assignment (likely H1 2027)
  • Potential FDA Advisory Committee meeting for ST-920
  • WORLD Symposium February 2027 for updated clinical data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PTC THERAPEUTICS, INC. 8-K PTCT ·Originating report

Sources · 12

Hover a chip for the title
1 ir.ptcbio.com2 ir.ptcbio.com3 investor.sangamo.com4 investor.sangamo.com5 investor.sangamo.com6 prnewswire.com7 novapharmanews.com8 sec.gov9 clinicaltrials.gov10 fabrydiseasenews.com11 ainvest.com12 alphai.io